FALCONE, ALFREDO
 Distribuzione geografica
Continente #
NA - Nord America 47.649
EU - Europa 17.367
AS - Asia 9.890
AF - Africa 482
SA - Sud America 180
OC - Oceania 51
Continente sconosciuto - Info sul continente non disponibili 18
AN - Antartide 1
Totale 75.638
Nazione #
US - Stati Uniti d'America 46.357
IT - Italia 6.315
CN - Cina 5.232
SE - Svezia 2.805
BG - Bulgaria 2.024
SG - Singapore 1.893
DE - Germania 1.449
CA - Canada 1.271
UA - Ucraina 1.106
TR - Turchia 981
RU - Federazione Russa 866
VN - Vietnam 865
GB - Regno Unito 800
FI - Finlandia 686
CH - Svizzera 534
HK - Hong Kong 523
FR - Francia 291
CI - Costa d'Avorio 279
IN - India 183
BR - Brasile 153
AT - Austria 137
BE - Belgio 83
SN - Senegal 79
NL - Olanda 71
NG - Nigeria 61
JP - Giappone 43
BJ - Benin 41
AU - Australia 34
ES - Italia 32
PK - Pakistan 32
KR - Corea 29
PL - Polonia 29
CZ - Repubblica Ceca 18
GR - Grecia 18
IE - Irlanda 18
EU - Europa 17
NZ - Nuova Zelanda 17
TW - Taiwan 16
MX - Messico 14
IL - Israele 12
IR - Iran 12
RO - Romania 12
DK - Danimarca 11
LU - Lussemburgo 11
MY - Malesia 11
HU - Ungheria 10
AR - Argentina 9
NO - Norvegia 9
ID - Indonesia 8
EG - Egitto 7
JO - Giordania 7
PT - Portogallo 7
LT - Lituania 6
PH - Filippine 6
SA - Arabia Saudita 6
CR - Costa Rica 5
NP - Nepal 5
TH - Thailandia 5
EC - Ecuador 4
PE - Perù 4
SK - Slovacchia (Repubblica Slovacca) 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
CO - Colombia 3
DZ - Algeria 3
KZ - Kazakistan 3
MG - Madagascar 3
AL - Albania 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BD - Bangladesh 2
BO - Bolivia 2
HR - Croazia 2
IQ - Iraq 2
LV - Lettonia 2
MA - Marocco 2
UZ - Uzbekistan 2
VE - Venezuela 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BS - Bahamas 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
IM - Isola di Man 1
KH - Cambogia 1
MD - Moldavia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
OM - Oman 1
PS - Palestinian Territory 1
RE - Reunion 1
RS - Serbia 1
SI - Slovenia 1
SM - San Marino 1
Totale 75.638
Città #
Woodbridge 7.970
Ann Arbor 5.026
Houston 4.540
Fairfield 4.067
Chandler 3.265
Milan 2.762
Ashburn 2.197
Santa Clara 2.075
Sofia 2.022
Seattle 1.788
Jacksonville 1.643
Wilmington 1.593
Cambridge 1.554
Shanghai 1.497
Ottawa 1.213
New York 1.195
Beijing 1.126
Singapore 1.021
Boardman 914
Princeton 852
Lawrence 788
Nanjing 703
Izmir 701
Medford 671
Serra 565
Bern 520
Hong Kong 496
Dearborn 448
Des Moines 418
Dong Ket 338
Jüchen 299
Nanchang 290
Rome 279
Abidjan 278
Istanbul 260
Düsseldorf 244
San Diego 220
Florence 216
Pisa 214
Redwood City 203
Boulder 172
London 162
Shenyang 153
Kunming 147
Ogden 132
Los Angeles 128
Vienna 128
Hebei 122
Changsha 117
Lancaster 105
Bremen 96
Jiaxing 92
Norwalk 92
Tianjin 92
Frankfurt am Main 91
Hefei 84
Dakar 79
Washington 76
Brussels 71
Fuzhou 65
Guangzhou 65
Lagos 59
Auburn Hills 52
Pune 52
Seacroft 52
Hangzhou 51
Orange 50
Phoenix 50
Chicago 45
Jinan 43
Cotonou 41
Council Bluffs 41
Grafing 41
Dallas 37
Falls Church 33
Detroit 31
Kent 31
Marseille 29
Positano 29
Verona 29
Helsinki 26
Toronto 25
Wuhan 24
Lanzhou 23
Lappeenranta 22
Chengdu 21
Warsaw 21
Cascina 19
Nürnberg 19
Multan 18
Paris 18
San Francisco 18
Nuremberg 17
São Paulo 17
Groningen 16
Hyderabad 16
Quanzhou 16
Zhengzhou 16
Bologna 15
Changchun 15
Totale 59.918
Nome #
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity 314
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 250
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 200
Zebrafish embryos as avatar of patients with pancreatic cancer: preliminary results of validation a new model toward personalized medicine 199
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach 189
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 185
Prognostic relevance of lymph node metastases and adjuvant treatment for patients with invasive intraductal papillary mucinous (IPMNs) of the pancreas 173
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC 173
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 171
OUTCOME OF SECOND-LINE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY WITH THE GONO FOLFOXIRI REGIMEN. 167
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 166
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region 164
5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer 162
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 162
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer 161
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy 161
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 160
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 159
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer 159
FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group 158
FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis 158
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 158
Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation 157
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 155
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 154
Preliminary experience with Xenotransplantation of pancreatic cancer samples in zebrafish embryos: towards personalized medicine 154
An interview with Alfredo Falcone and Lisa Salvatore: RECOURSE and trifluridine/tipiracil in metastatic colorectal cancer 154
Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine 153
The effect of bevacizumab plus chemotherapy on the immunological profile of advanced colorectal cancer patients 152
First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study 151
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 151
Optimal approach to potentially resectable liver metastases from colorectal cancer 150
KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 149
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 148
Long-term outcome of unresectable metastatic colorectal cancer: does “adjuvant” chemotherapy play a role after resection? 148
Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(MCRC): Updated results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study 147
Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the “polmone toscano group” (POLTO) 146
Cancer pharmacogenomics: germline DNA, tumor DNA, or both? 146
Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.) 146
A PILOT STUDY OF A DAY ONE AND EIGHT EVERY THREE WEEKS ADMINISTRATION OF DOCETAXEL IN METASTATIC CANCER PATIENTS 146
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis 146
A phase II study of oral doxifluridine in elderly patients with advanced non small cell lung cancer 145
Genetic analysis of cytidine deaminase (CDA) for the prediction of response to chemotherapy and survival in advanced non-small-cell lung cancer (NSCLC) patients treated with gemcitabine 145
Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer (MCRC) 145
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 145
TAS-102 for the treatment of metastatic colorectal cancer 145
Outcome of initially unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases (mts) 143
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 143
Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer 142
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 142
Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC) 142
Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly 141
Mucinous histology in advanced colorectal cancer patients treated with first-line irinotecan-and/or oxaliplatin-based chemotherapy 141
Palliative treatment of unresectable metastatic colorectal cancer 141
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role 141
5-fluorouracil enhances azidothymidine cytotoxicity. In vitro, in vivo and biochemical studies 140
Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study 140
Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small cell lung cancer 140
Cisplatin plus gemcitabine as adjuvant chemotherapy for resected non-small cell lung cancer (NSCLC): a phase II tolerability study 140
A PHASE ii TRIAL OF FIXED-DOSE RATE GEMCITABINE PLUS CAPECITABINE IN METASTATIC/ADVANCED BILIARY TRACT CANCER PATIENTS. 140
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer 139
KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 139
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 139
Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer? 138
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 138
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 138
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer 137
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer 137
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 137
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 137
Second-line therapy for advanced pancreatic cancer: Evaluation of prognostic factors and review of current literature 137
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 136
Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib 135
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 135
Variations in the Interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer 135
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 135
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer 135
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 135
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 135
Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): a phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination 134
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by Irinotecan (IR) + 5-FU/LV (IRFL) followed by Docetaxel (T) + 5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): preliminary results of a phase II trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 134
Economic evaluation of the cost of treating advanced gastric cancer (AGC) with capecitabine/cisplatin (XP) vs. 5-FU/cisplatin (FP) regimens in an Italian setting 133
A phase II pilot study of sequential chemo-immunotherapy with capecitabina+ interferon α2A (IFN) followed by interleukina-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC): on behalf of the Gruppo Oncologico Nord Ovest (G.O.N.O.) 133
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 133
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 133
Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib ( C ) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results 132
Nuclear factor kB (NF-kB) may predict efficacy of cetuximab therapy in EGFR-positive colorectal cancer 132
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 132
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 132
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. 132
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 132
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 132
A randomised phase II study of cetuximab plus gemcitabine/cisplatin combination in advanced pancreatic cancer (APC) 131
The impact of cetuximab on the gemcitabine/cisplatin combination in first-line treatment of EGFR-positive advanced pancreatic cancer (APC): A randomized phase II trial of GISCAD 131
Radium 223 dichloride: A multidisciplinary approach to metastatic castration-resistant prostate cancer 131
Feasibility and efficacy of 223Ra-dichloride (223Ra) to treat bone metastases in patients (pts) with castration resistant prostate cancer (mCRPC) 131
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 131
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer 131
Phase II trial of 5-fluorouracil and the natural L isomer of folinic acid in the treatment of advanced colorectal carcinoma 130
Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients 130
Totale 14.870
Categoria #
all - tutte 211.240
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 211.240


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.279 0 0 0 0 0 0 0 907 1.338 758 1.015 261
2020/20216.561 592 389 348 274 691 511 478 528 673 530 384 1.163
2021/20227.610 90 506 190 432 1.488 1.237 141 305 339 265 474 2.143
2022/20238.514 1.149 935 504 790 1.105 1.171 46 682 1.405 52 593 82
2023/20248.893 1.374 1.213 1.178 711 1.395 1.348 217 259 154 134 198 712
2024/20257.874 111 887 274 1.049 1.521 2.327 1.247 458 0 0 0 0
Totale 76.614